| Q44049813 | "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer |
| Q33850471 | A Resident's Perspective of Ovarian Cancer |
| Q87399727 | A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers |
| Q89475216 | A dog oviduct-on-a-chip model of serous tubal intraepithelial carcinoma |
| Q35100056 | A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation |
| Q54296090 | A mouse model for endometrioid ovarian cancer arising from the distal oviduct. |
| Q58580413 | A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy |
| Q34387999 | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
| Q37225222 | ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas |
| Q38941768 | Abdominopelvic washings in gynecologic pathology: A comprehensive review |
| Q37676705 | Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis |
| Q30423597 | Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer |
| Q36670219 | Age dependent increase in prostaglandin pathway coincides with onset of ovarian cancer in laying hens |
| Q35391648 | Alginate hydrogels for three-dimensional organ culture of ovaries and oviducts |
| Q40115732 | Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. |
| Q53247081 | Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: implications for ovarian carcinogenesis. |
| Q47896747 | Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer |
| Q34812090 | Avian WNT4 in the female reproductive tracts: potential role of oviduct development and ovarian carcinogenesis |
| Q36574436 | BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer |
| Q38039167 | BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations |
| Q55461779 | BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. |
| Q89520839 | Before it catches the eye… |
| Q88594525 | Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations |
| Q91241127 | Breastfeeding factors and risk of epithelial ovarian cancer |
| Q33859857 | CA125 in ovarian cancer |
| Q48148897 | CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. |
| Q41266914 | Cancer of the ovary, fallopian tube, and peritoneum |
| Q85015064 | Cancer of the ovary, fallopian tube, and peritoneum |
| Q59809876 | Cell Origins of High-Grade Serous Ovarian Cancer |
| Q45933729 | Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. |
| Q37756401 | Characterization and comparison of precursors of ovarian and endometrial carcinoma: parts I and II. |
| Q58794800 | Characterization of Primary Cilia in Normal Fallopian Tube Epithelium and Serous Tubal Intraepithelial Carcinoma |
| Q35759295 | Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours |
| Q30235030 | Chlamydia trachomatis Genital Infections |
| Q35137772 | Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors |
| Q53177289 | Chlamydia trachomatis, Chlamydial Heat Shock Protein 60 and Anti-Chlamydial Antibodies in Women with Epithelial Ovarian Tumors. |
| Q81571883 | Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma |
| Q34875061 | Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation |
| Q37392946 | Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. |
| Q34378112 | Coming into focus: the nonovarian origins of ovarian cancer. |
| Q37729985 | Complications from Surgeries Related to Ovarian Cancer Screening |
| Q35624957 | Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study |
| Q37232123 | Critical molecular abnormalities in high-grade serous carcinoma of the ovary |
| Q45072344 | Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. |
| Q27028117 | Current status and evolution of preclinical drug development models of epithelial ovarian cancer |
| Q51131528 | Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid. |
| Q37302337 | Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy |
| Q38790328 | DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression |
| Q34595670 | Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma |
| Q85208852 | Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology--a prospective comparative study |
| Q34397197 | Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer |
| Q84916174 | Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology |
| Q34282708 | Development of a syngeneic mouse model of epithelial ovarian cancer |
| Q34305493 | Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer |
| Q34305434 | Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. |
| Q34511086 | Distinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomas |
| Q31141440 | Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification |
| Q82682167 | Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? |
| Q34103978 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary |
| Q37785214 | Drug Development for Cancer Chemoprevention: Focus on Molecular Targets |
| Q36868408 | Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis |
| Q83275355 | Early detection of ovarian cancer in symptomatic women |
| Q35749439 | Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study |
| Q39214181 | Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial-stromal interaction |
| Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
| Q30450816 | Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer |
| Q35830931 | Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 |
| Q34687073 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study |
| Q49342245 | Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia |
| Q33588196 | Expression signatures of TP53 mutations in serous ovarian cancers |
| Q37200903 | FGF18 as a prognostic and therapeutic biomarker in ovarian cancer |
| Q92966596 | Fallopian Tube Epithelial Changes in Ovarian Serous Tumors Compared with Control Group: A Single-Center Study |
| Q43158887 | Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. |
| Q80134053 | Fallopian tube cancer: stepchild or mother? |
| Q34604042 | Fallopian tube origin of supposed ovarian high-grade serous carcinomas |
| Q35014713 | Fallopian tube prolapse after hysterectomy: a systematic review |
| Q36897742 | Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? |
| Q36309548 | Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis |
| Q56489480 | Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis |
| Q37224153 | Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis |
| Q55247640 | Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. |
| Q45968079 | Genetic risk factors for ovarian cancer and their role for endometriosis risk. |
| Q34453723 | Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium |
| Q28742817 | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial |
| Q37144104 | Genomic analysis of epithelial ovarian cancer |
| Q33645478 | Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells |
| Q46449018 | Hereditary gynecologic cancers |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q35844827 | High-grade serous ovarian cancer arises from fallopian tube in a mouse model |
| Q60920553 | Hysterectomy and opportunistic salpingectomy (HOPPSA): study protocol for a register-based randomized controlled trial |
| Q34468574 | IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis |
| Q34504360 | IMP3 signatures of fallopian tube: a risk for pelvic serous cancers |
| Q33775466 | Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers |
| Q33387074 | Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. |
| Q40028239 | Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. |
| Q38820442 | In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose. |
| Q37610093 | In vivo time-serial multi-modality optical imaging in a mouse model of ovarian tumorigenesis |
| Q33802761 | Inhibitory role of prohibitin in human ovarian epithelial cancer |
| Q37532651 | Investigation of mammographic breast density as a risk factor for ovarian cancer |
| Q27002945 | Investigative pathology: leading the post-genomic revolution |
| Q45087026 | Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer |
| Q90557077 | Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions |
| Q36285026 | Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma |
| Q51531612 | Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors |
| Q35237915 | Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome |
| Q33527712 | Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary |
| Q38068618 | Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles |
| Q37014152 | Mathematical models of breast and ovarian cancers. |
| Q33508232 | MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary |
| Q37119791 | Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms |
| Q36039369 | Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection |
| Q37197308 | Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium |
| Q37293672 | Molecular pathogenesis of endometrial and ovarian cancer |
| Q85096106 | Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases |
| Q34279411 | Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics |
| Q27333756 | Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. |
| Q43703057 | Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol |
| Q37119411 | New insights into the pathogenesis of serous ovarian cancer and its clinical impact |
| Q35845033 | Nonovarian origins of ovarian cancer |
| Q88847543 | Of mice and women - Non-ovarian origins of "ovarian" cancer |
| Q35111420 | On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research |
| Q35597082 | Oncolytic virotherapy for ovarian cancer |
| Q34473693 | Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. |
| Q37594378 | Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry |
| Q33850454 | Ovarian Cancer Incidence Corrected for Oophorectomy |
| Q91656739 | Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting |
| Q82238526 | Ovarian cancer |
| Q39421659 | Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening |
| Q27004471 | Ovarian cancer screening--current status, future directions |
| Q37415611 | Ovarian cancer update: lessons from morphology, molecules, and mice |
| Q37113828 | Ovarian cancer: involvement of the matrix metalloproteinases |
| Q34493156 | Ovary and fimbrial stem cells: biology, niche and cancer origins |
| Q34063581 | Ovulation and extra-ovarian origin of ovarian cancer |
| Q47160060 | PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state |
| Q37101060 | Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications |
| Q90565268 | Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience |
| Q26829125 | Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment |
| Q51554695 | Pax8: a marker for carcinoma of Müllerian origin in serous effusions. |
| Q36966258 | Population distribution of lifetime risk of ovarian cancer in the United States |
| Q41110434 | Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma |
| Q34803840 | Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma |
| Q37622105 | Precursors of endometrial and ovarian carcinoma |
| Q35886692 | Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. |
| Q34639149 | Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases |
| Q39287947 | Primary culture and immortalization of human fallopian tube secretory epithelial cells |
| Q44264768 | Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland |
| Q37741774 | Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women |
| Q44693364 | Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology |
| Q39219310 | Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers |
| Q44293241 | Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate |
| Q86542886 | Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere |
| Q39756023 | Protease inhibitor SERPINA1 expression in epithelial ovarian cancer |
| Q34126627 | Proteomics and ovarian cancer: integrating proteomics information into clinical care |
| Q37620476 | Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. |
| Q37553978 | Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management |
| Q33759421 | Reliable in vitro studies require appropriate ovarian cancer cell lines |
| Q92509689 | Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up |
| Q38185144 | Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing |
| Q34764768 | Risk factors for ovarian cancer: an overview with emphasis on hormonal factors |
| Q37362164 | Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery |
| Q36313479 | Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. |
| Q57688855 | Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations |
| Q39064164 | Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives |
| Q39196159 | Risk-reducing salpingectomy: Let us be opportunistic |
| Q94325832 | Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations |
| Q38419814 | Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. |
| Q46303839 | Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis |
| Q38978839 | Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management |
| Q33888942 | Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase |
| Q36652107 | Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis |
| Q35624638 | Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar |
| Q27009306 | Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer |
| Q35859678 | Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors |
| Q30651522 | Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation |
| Q52763151 | Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis. |
| Q49924941 | The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium. |
| Q48291586 | The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer |
| Q39409441 | The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. |
| Q61797630 | The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients |
| Q28302089 | The cell of origin of ovarian epithelial tumours |
| Q41294690 | The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer |
| Q38350476 | The domestic chicken: Causes and consequences of an egg a day. |
| Q38187331 | The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift |
| Q50991668 | The hen as a model of ovarian cancer. |
| Q36810356 | The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms |
| Q35077893 | The immunomodulating roles of glycoproteins in epithelial ovarian cancer |
| Q36802249 | The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer |
| Q34288214 | The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. |
| Q35507860 | The new face of ovarian cancer modeling: better prospects for detection and treatment. |
| Q53652034 | The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. |
| Q91869661 | The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG) |
| Q37293916 | The role of microRNAs in ovarian cancer initiation and progression |
| Q61925515 | The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer |
| Q84830246 | The tubal hypothesis of ovarian cancer: caution needed |
| Q87993586 | Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US |
| Q38645763 | Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection |
| Q84401609 | Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls |
| Q33865112 | Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin? |
| Q36750166 | Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. |
| Q33850475 | Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials |
| Q33848119 | Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women |
| Q37672753 | VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. |
| Q33994590 | Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. |
| Q39845438 | Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents |
| Q36685324 | YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. |
| Q53738265 | [Hereditary breast and ovarian cancer]. |
| Q53305324 | [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. |
| Q64062380 | infection in primary fallopian tube and high-grade serous ovarian cancers: a pilot study |